¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æ"/> ÏÖÔÚ £¬ÕÅijÒòÉæÏÓÕ©Æ­×ïÒѱ»ÐÌʾÐÁô¡£"/>

ÌÚ²©tengbo9885¹ÙÍø

¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æ

¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æ

¡¶¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æ¡·¾çÇé¼ò½é£ºÏÖÔÚÕÅijÒòÉæÏÓÕ©Æ­×ïÒѱ»ÐÌʾÐÁô¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æÕÅСǿ¶ÔêØ¶ùÒª¼Þ¸ø×Ô¼º²¢²»ÔõôÉË·çÕâ¸öÁ³ÉÏÔàÙâÙâµÄѾͷ¿´ÉÏÈ¥²»ËãºÜÄÑ¿´¿ÉÊÇËûÁ¬Âü¶ù¶¼Ã»ÐËȤ¶ÔÕâ¸öδ³ÉÄêµÄСŮÈ˾͸ü²»¸ÐÐËȤÁËÕÅСǿµÄÌáÒéÈÃêØ¶ùÂúÁ³¾øÍûÃ͵ص¹×ª¼ýͷָןíÁü¼â½ÐµÀ£ºÏëÒ²±ðÏëÎÒ²»»áÈÃËûÃǼÓÈëÄãµÄÄãËÀÁËÕâÌõÐİÉÎÒÇéÔ¸ËÀÔÚÄãÑÛǰҲ²»ÔÊÐí¶øËïÎò¿ÕÕâ¸öÃû×ÖÒ²ÕýÊÇËûµÄʦ¸¸ÆÐÌá×æÊ¦¸øÆðµÄ

¡¶¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æ¡·ÊÓÆµËµÃ÷£º¶þÈËÔÚ½øÈë֮ǰÓÖ×öÁ˳ä·Ö×¼±¸ÔõÑùÇø·Ö·Çµä·¶CMLÓëÆäËû¹ÇËèÔöÖ³ÐÔÖ×ÁöÔ­´´2020-09-12 17:53¡¤Ò½ÂöͨѪҺ¿Æ×÷ÕߣºÀ¶¾¨Ïþ»¢±¾ÎÄΪ×÷ÕßÊÚȨҽÂöͨÐû²¼δ¾­ÊÚȨÇëÎð×ªÔØ·Çµä·¶ÂýÐÔËèϵ°×Ѫ²¡(aCML)BCR-ABL1(£­)ÊÇÒ»ÖÖÓÐÊýµÄѪҺ¶ñÐÔÖ×ÁöÊôÓÚWHO¹ÇËèÖ×Áö·ÖÀàÖеĹÇËèÔöÉúÒì³£/¹ÇËèÔöÖ³ÐÔÖ×Áö(MDS/MPN)aCML×î³õ±»ÃüÃûΪ·Çµä·¶ÐÎʽµÄÂýÐÔËèϵ°×Ѫ²¡(CML)¼¸Ê®ÄêÀ´aCMLµÄÕï¶Ï±ê×¼±¬·¢ÁËÏÔÖø×ª±äÈ»¶øaCMLµÄÕï¶Ïȱ·¦ÌØÕ÷ÐÔ¶ÔÆä·Ö×Ó»ùÒòͼÆ×µÄÈÕÒæÏàʶÓÐÖúÓÚÇø·ÖaCMLÓëÆäËûMDS/MPNºÍMPNsÒÔ±ãÔçÆÚÆô¶¯ÖÎÁƺ͸ÄÉÆÔ¤ºóaCMLµÄÁÙ´²ºÍÐÎ̬±íÐÍaCML»¼ÕßÌåÏÖ³ö¹ÇËèÔöÉúÌØÕ÷°üÀ¨°×ϸ°ûÔö¶àºÍÆ¢Ö×´ó¿É°éÓÐѪÐéºÍѪС°åïÔÌ­WBC¼ÆÊý¡Ý13¡Á109/LÍâÖÜѪÖб£´æÖÁÉÙ10%µÄδ³ÉÊìÁ£Ï¸°û£¨°üÀ¨ÔçÓ×Á£Ï¸°û¡¢ÖÐÓ×Á£Ï¸°ûºÍÍíÓ×Á£Ï¸°û£©ÒÔÖØ¶ÈÁ£Ï¸°ûÌìÉúÕϰ­ÎªÌØÕ÷²»±£´æµ¥ºËϸ°ûÔö¶à£¨ÍâÖÜѪµ¥ºËϸ°û<ѪҺ°×ϸ°ûµÄ10%ѪҺ¼ÆÊý< 1¡Á109/L£©ÍâÖÜѪÖеÄÊȼîÐÔÁ£Ï¸°û< 2%¹ÇËèºÍÍâÖÜѪÖÐԭʼϸ°û£¨°üÀ¨Ó×µ¥ºËϸ°û£©< 20%ÐÎ̬ѧÉÏaCMLÍâÖÜѪÌåÏÖΪÑÏÖØÁ£Ï¸°ûÒìÐÍÔöÉúÌØÕ÷ÐÔÌåÏÖ°üÀ¨ÖÐÐÔÁ£Ï¸°ûµÄȾɫÖÊÌ«¹ýȺ¼¯ÒÔ¼°ºËÆÆËéÏóÒì³£ÈçºËµÍ·ÖÒ¶(¼ÙPelger-HuetºË)»ò¶à·ÖÒ¶°û½¬¿É³Ê¿ÅÁ£ïÔÌ­ÉõÖÁÒì³£Ôö´ó¹ÇËèϸ°û¹ý¶àÒÔÁ£Ï¸°ûΪÖ÷³ÊÏÔ×ÅÒìÐÍÔöÉú°ëÊýÒÔÉϲ¡ÀýÓкìϵ·¢Óý²»Á¼ºÍÒ»¶¨Ë®Æ½µÄ¾ÞºËϸ°û·¢Óý²»Á¼±ðµÄ¿É¼û²î±ðˮƽµÄÍøÓ²ÂѰ×ÏËάÔöÌíWHO 2016ÄêÌá³öµÄaCMLÒÔ¼°¾ßÓÐÏàËÆÌØÕ÷µÄËèϵÖ×ÁöÕï¶Ï±ê×¼×ܽá¼ûϱí×¢£ºaCML·Çµä·¶ÂýÐÔËèÐÔ°×Ѫ²¡£»BM¹ÇË裻CMMLÂýÐÔÁ£µ¥ºËϸ°û°×Ѫ²¡£»ETÔ­·¢ÐÔѪС°åÔö¶àÖ¢£»MDS/MPN-RS-T¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö°é»·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àÖ¢£»MDS/MPN-U¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö²»¿É·ÖÀࣻPVÕæÐÔºìϸ°ûÔö¶àÖ¢£»PBÍâÖÜѪaCMLµÄϸ°ûÒÅ´«Ñ§ÌØÕ÷Ö»¹Üƾ֤½ç˵aCMLȱ·¦·Ñ³ÇȾɫÌå¼°BCR-ABL1ÖØÅŵ«Ô¼Ò»°ëµÄaCML²¡Àý±£´æÏ¸°ûÒÅ´«Ñ§»û±ä°üÀ¨8ÈýÌå¡¢YȾɫÌåȱʧ¡¢20ºÅȾɫÌ峤±Û²¿·Öȱʧ(20q-)¡¢17ºÅµÈ±ÛȾɫÌ塢ɿ¼°12¡¢13¡¢14¡¢17ºÅȾɫÌåµÄȱʧºÍÖØ´óºËÐÍÈ»¶øÕâЩϸ°ûÒÅ´«Ñ§Òì³£¾ù·ÇaCMLËùÌØÓÐÇÒÏ൱¶àµÄ²¡Àý£¨¸ß´ï80%£©¿É¾ßÓÐÕý³£µÄºËÐÍaCMLµÄ¸´·¢ÐÔ»ùÒòÍ»±äaCMLÖÐ×î³£¼ûµÄÍ»±ä»ùÒòÊÇASXL1¡¢NRAS¡¢SETBP1¡¢SRSF2ºÍTET2×î½üÑо¿Åú×¢69%µÄaCML²¡ÀýÔÚ±í¹ÛÒÅ´«ÐÞÊλùÒòTET2¡¢IDH1/2¡¢DNMT3A¡¢EZH2ºÍ/»òASXL1ÖÐЯ´øÖÁÉÙÒ»ÖÖÍ»±äͼ1×ܽáÁËaCMLÖÐ×î³£¼ûµÄÍ»±äÔõÑùÕï¶ÏaCMLÕï¶ÏaCMLÓ¦»ùÓÚʶ±ðÆäÌØÕ÷ÐÔµÄÐÎ̬ѧ¡¢ÊµÑéÊÒºÍÒÅ´«Ñ§ÌØÕ÷ɨ³ý¾ßÓÐÃ÷È·ÒÅ´«Ñ§¸Ä±äµÄÆäËûËèϵ¶ñÐÔÖ×ÁöÆðÔ´¼ì²éÓ¦×ÅÖØÓÚɨ³ýBCR-ABL1ÈÚºÏƾ֤½ç˵CMLÒ»¶¨±£´æBCR-ABL1Èں϶øaCMLÖÐÎÞ´ËÕ÷Ïó»¹Ó¦É¨³ýÆäËû²¡ÀíÐÔ»ùÒòÍ»±äÈçPDGFRA¡¢PDGFRB¡¢FGFR1»òPCM1-JAK2ÈںϼøÓÚÕâÐ©ÖØÅÅ¿ÉÄܱ£´æÒÅ´«Ñ§ÒþÃØ³ýÁ˺ËÐÍÆÊÎöÔÚÈ·¶¨aCMLÕï¶Ï֮ǰӦ˼Á¿FISH¼ì²â»òRNA-²âÐòÀ´É¨³ýÉÏÊöÇéÐÎPDGFRBÖØÅŵÄËèϵÖ×Áö»¼Õß¿ÉÌåÏÖΪMDS/MPNÑù±íÐÍÐÎÌ¬Ñ§ÌØÕ÷ÓëaCMLÏàËÆÏÖÒÑÒâʶµ½PDGFRBÖØÅŵÄËèϵÖ×Áö¾ßÓкÜÊÇÆÕ±éµÄ±íÐͲ¢²»¾ÖÏÞÓÚ°éÊÈËáÐÔÁ£Ï¸°ûÔö¶àÌØÕ÷µÄCMMLʶ±ðÖØÅÅ£¨ÈçPDGFRB/PDGFRA£©ÖÁ¹ØÖ÷ÒªÓÉÓÚÓëaCMLÏà±È¾ßÓÐÕâÀàÌØÕ÷µÄ¼²²¡¶ÔÀÒ°±ËἤøÒÖÖÆ¼Á£¨ÒÁÂíÌæÄᣩµÄÃô¸ÐÐÔ¸ßÔ¤ºó½ÏºÃÇø·ÖaCMLÓëijЩBCR-ABL1£¨-£©µÄMPNs £¨CNLÔ­·¢ÐÔ¹ÇËèÏËά»¯[PMF]£©ºÍMDS/MPN£¨CMMLºÍMDS/MPN-U£©¾ßÓÐÌôÕ½ÐÔMPN¼ÈÍùÊ·¿Éɨ³ýaCMLµÄÕï¶Ï¹ÇËè»î¼ì·¢Ã÷µä·¶µÄMPNÐÎ̬ѧЧ¹û£¨ÓÈÆäÊÇÔÚûÓÐÏÔÖøÁ£Ï¸°û·¢Óý²»Á¼µÄÇéÐÎÏ£©ºÍMPNÏà¹ØÍ»±ä£¨ÔÚJAK2¡¢CALR»òMPLÖУ©Ê±²»ÇãÏòaCMLÌáÐÑPMF¡¢ÕæÐÔºìϸ°ûÔö¶àÖ¢(PV)»òÔ­·¢ÐÔѪС°åÔö¶àÖ¢(ET)ÌáÐÑÐÔµÄÍ»±äÌØÕ÷£¨ÈçSETBP1/ETNK1Í»±ä£©ÇÒ¾ßÓÐÇкÏÕï¶Ï±ê×¼µÄÌØÕ÷ÓÐÖúÓÚ֤ʵaCMLÍâÖÜѪÖе¥ºËϸ°ûµÄ°Ù·Ö±ÈÊÇÇø·ÖaCMLºÍCMMLµÄÖ÷ÒªÌØÕ÷ÔÚaCMLÖÐʼÖÕµÍÓÚ10%£¨ºÜÉÙ>2%£©ϸ°û»¯Ñ§È¾É«Èç·ÇÌØÒìÐÔõ¥Ã¸(NSE)ÓÐÖúÓÚÔÚÒÉÄѲ¡ÀýÖмì²âµ¥ºËϸ°ûÁíÒ»¸ö¸üÖ÷¹ÛµÄÐÎÌ¬Ñ§Çø±ðÊÇaCML±£´æ¸üÑÏÖØµÄÁ£Ï¸°û·¢Óý²»Á¼Ö»¹Üȱ·¦ÆÀ¹À·¢Óý²»Á¼ÑÏÖØË®Æ½µÄÏêϸָÄÏÐèÒª¾ÙÐÐÌúȾɫÒÔɨ³ý°éÓл·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àµÄMDS/MPN-RS-TÔÚÒÔÔöÖ³ÌØÕ÷ΪÖ÷ÇÒÒÔÖÐÐÔÁ£Ï¸°ûΪÖ÷µÄ»¼ÕßÖÐCSF3RÍ»±äӦǿÁÒÌáÐÑCNLÇø·ÖaCMLÓëMDS/MPN-U½ÏΪÄÑÌâaCML»¼ÕßµÄÖÐλWBC¼ÆÊýÏÔÖøÉý¸ßµ«·Ç¾ø¶ÔÌØÕ÷Ò»Á¬ÐÔµ¥ºËϸ°ûÔö¶àÌáÐÑCMMLTET2+SRSF2Í»±ä¶ÔCMML¾ßÓÐÏà¶ÔÌØÒìÐÔÖ»¹ÜÁ½ÕßÔÚaCMLÖоù¿É¼ûÒ»ÖÖеÄaCMLÕï¶ÏÁ÷³ÌС½áÓÉÓÚ·¢²¡Âʵ͡¢Õï¶Ï±ê×¼Ò»Ö±¸üкÍȱ·¦·Ö×ÓÒÅ´«Ñ§µÄÃ÷È··Çµä·¶ÂýÐÔËèϵ°×Ѫ²¡Ò»Ö±ÊÇÒ»ÖÖÄÑÒÔÕï¶ÏµÄMDS/MPNËæ×ŶԻùÒò×é´óÊý¾ÝµÄÒ»Ö±ÍÚ¾òÒÑ·¢Ã÷SETBP1ºÍETNK1µÄÖØ¸´Í»±ä¶ÔaCMLÓÐÌáÐÑ×÷ÓÿÉÒÔÍŽáʵÑéÊÒºÍÐÎ̬ѧЧ¹ûÀ´Çø·ÖaCMLºÍÆäËû·Ñ³ÇÒõÐÔ¹ÇËèÔöÖ³ÐÔÖ×ÁöÈ»¶øÍ»±äµÄͬʱ±¬·¢ÊÇ·ñ»á¸Ä±äaCMLµÄ¼²²¡±íÐͺÍÖÎÁÆ·´Ó¦Éв»Ã÷È·²Î¿¼ÎÄÏ×£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.¿´À´¹ù¾§¾§ºÍ»ôÆô¸ÕÕâ¶Ô×éºÏÔÚÌåÓý¹¤ÒµÕâ¸ö´óÎę̀ÉÏÉÐÓиü¶à¾«²ÊÒªÉÏÑÝÄØ

µ«ÔÚËý¶áµÃµÄÈÙÒ«±³ºóÏÖʵÉÏÒþ²ØÁËÎÞÊýµÄÐÁËáºÍº¹Ë®³ÂÈôÁÕÔÚѵÁ·ÖÐÒ»Ö±×·ÇóÍêÉÆ²»ÁßÒ»ÇмÛǮȥÓâÔ½×Ô¼ºµÄ¼«ÏÞÿһ´Îˤµ¹Ëý¶¼ÏñÄÇÖ»ÍçÇ¿µÄСÄñÆð¾¢ÕñÓðÏò¿Õ°¿Ïè×ÝÈ»ÔâÓö²¨ÕÛËýÒ²´Ó²»ÑÔÆúËýÃ÷È·Ö»ÓÐÅöײ²Å»ªÒý·¢³ö×Ô¼ºÐÄÌïµÄ»ð»¨ÕýÓÉÓÚÕâ·ÝÖ´×ÅÓë¿ÌÒâ³É¼¨ÁËËýµÄ´«Ææ

¸üУº

2025-10-10 11:46:49

±¸×¢£º
¹úÓï
ÆÀ¼Û£º
¹úÄ£ÊÒÄÚ´óµ¨Ë½ÅÄͼƬÒÕÊõÓëÕùÒé²¢´æ

Ñ¡¼¯²¥·Å
ÅÅÐò

Ñ¡Ôñ²¥·ÅÔ´
¿ìËÙ²¥·Å¢Ù
Ê×Ò³
Ó°Ï·
Ò»Á¬¾ç
×ÛÒÕ
¶¯Âþ
APP
ÍøÕ¾µØÍ¼